These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 28089455)

  • 1. Comparison of transcatheter aortic valve implantation with the newest-generation Sapien 3 vs. Direct Flow Medical valve in a single center cohort.
    Schulz E; Jabs A; Tamm A; Herz P; Schulz A; Gori T; von Bardeleben S; Kasper-König W; Hink U; Vahl CF; Münzel T
    Int J Cardiol; 2017 Apr; 232():186-191. PubMed ID: 28089455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfemoral aortic valve implantation is more successful with the Edwards Sapien 3 compared with the Edwards XT for the treatment of symptomatic severe aortic stenosis.
    Gonska B; Seeger J; Junker A; Rodewald C; Trepte U; Scharnbeck D; Rottbauer W; Wöhrle J
    Arch Cardiovasc Dis; 2018; 111(8-9):470-479. PubMed ID: 29128473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The balloon-expandable Edwards Sapien 3 valve is superior to the self-expanding Medtronic CoreValve in patients with severe aortic stenosis undergoing transfemoral aortic valve implantation.
    Gonska B; Seeger J; Baarts J; Rodewald C; Scharnbeck D; Rottbauer W; Wöhrle J
    J Cardiol; 2017 Jun; 69(6):877-882. PubMed ID: 27614379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of new-generation transcatheter aortic valves: insights from the Israeli transcatheter aortic valve replacement registry.
    Finkelstein A; Steinvil A; Rozenbaum Z; Halkin A; Banai S; Barbash I; Guetta V; Segev A; Danenberg H; Orvin K; Assa HV; Assali A; Kornowski R
    Clin Res Cardiol; 2019 Apr; 108(4):430-437. PubMed ID: 30238186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome With the Repositionable and Retrievable Boston Scientific Lotus Valve Compared With the Balloon-Expandable Edwards Sapien 3 Valve in Patients Undergoing Transfemoral Aortic Valve Replacement.
    Seeger J; Gonska B; Rottbauer W; Wöhrle J
    Circ Cardiovasc Interv; 2017 Jun; 10(6):. PubMed ID: 28566290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Balloon-Expandable Transcatheter Heart Valve: A Single-Center Experience.
    Husser O; Pellegrini C; Kessler T; Burgdorf C; Thaller H; Mayr NP; Ott I; Kasel AM; Schunkert H; Kastrati A; Hengstenberg C
    JACC Cardiovasc Interv; 2015 Dec; 8(14):1809-16. PubMed ID: 26718512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the fully repositionable and retrievable Boston Lotus and direct flow medical valves for the treatment of severe aortic stenosis: A single center experience.
    Giannini F; Latib A; Montorfano M; Ruparelia N; Romano V; Longoni M; Ferri L; Jabbour R; Mangieri A; Regazzoli D; Ancona M; Buzzatti N; Azzalini L; Tanaka A; Agricola E; Chieffo A; Alfieri O; Colombo A
    Catheter Cardiovasc Interv; 2018 Apr; 91(5):966-974. PubMed ID: 28941127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Direct Comparison of Self-Expandable Portico Versus Balloon-Expandable Sapien 3 Devices for Transcatheter Aortic Valve Replacement: A Case-Matched Cohort Study.
    Mas-Peiro S; Seppelt PC; Weiler H; Mohr GL; Papadopoulos N; Walther T; Zeiher AM; Fichtlscherer S; Vasa-Nicotera M
    J Invasive Cardiol; 2019 Jul; 31(7):E199-E204. PubMed ID: 31257214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfemoral aortic valve implantation with new-generation devices: the repositionable Lotus vs. the balloon-expandable Edwards Sapien 3 valve.
    Nai Fovino L; Badawy MRA; Fraccaro C; D'Onofrio A; Purita PAM; Frigo AC; Tellaroli P; Mauro A; Tusa M; Napodano M; Gerosa G; Iliceto S; Bedogni F; AbdelRheim AER; Tarantini G
    J Cardiovasc Med (Hagerstown); 2018 Nov; 19(11):655-663. PubMed ID: 30299408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propensity-matched comparison between Direct Flow Medical, Medtronic Corevalve, and Edwards Sapien XT prostheses: Device success, thirty-day safety, and mortality.
    Zhang Y; Pyxaras SA; Wolf A; Schmitz T; Naber CK
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1217-25. PubMed ID: 25581785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfemoral aortic valve implantation with the repositionable Lotus valve compared with the balloon-expandable Edwards Sapien 3 valve.
    Wöhrle J; Gonska B; Rodewald C; Trepte U; Koch S; Scharnbeck D; Seeger J; Markovic S; Rottbauer W
    Int J Cardiol; 2015 Sep; 195():171-5. PubMed ID: 26043152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome and paravalvular leakage of the new balloon-expandable Edwards Sapien 3 valve in comparison to its predecessor model (Edwards Sapien XT) in patients undergoing transfemoral aortic valve replacement.
    Bocksch W; Grossmann B; Geisler T; Steeg M; Droppa M; Jorbenadze R; Haap M; Gawaz M; Fateh-Moghadam S
    Catheter Cardiovasc Interv; 2016 Sep; 88(3):466-75. PubMed ID: 27184353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct transfemoral transcatheter aortic valve implantation without balloon pre-dilatation using the Edwards Sapien XT valve.
    Bandali A; Parry-Williams G; Kassam A; Palmer S; Williams PD; de Belder MA; Owens A; Goodwin A; Muir DF
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):978-985. PubMed ID: 27189391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of the percutaneous transaxillary access for transcatheter aortic valve implantation using various transcatheter heart valves in 100 consecutive patients.
    Schäfer U; Deuschl F; Schofer N; Frerker C; Schmidt T; Kuck KH; Kreidel F; Schirmer J; Mizote I; Reichenspurner H; Blankenberg S; Treede H; Conradi L
    Int J Cardiol; 2017 Apr; 232():247-254. PubMed ID: 28118931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aortic regurgitation after transcatheter aortic valve implantation with balloon- and self-expandable prostheses: a pooled analysis from a 2-center experience.
    Abdel-Wahab M; Comberg T; Büttner HJ; El-Mawardy M; Chatani K; Gick M; Geist V; Richardt G; Neumann FJ;
    JACC Cardiovasc Interv; 2014 Mar; 7(3):284-92. PubMed ID: 24650401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early versus newer generation transcatheter heart valves for transcatheter aortic valve implantation: Echocardiographic and hemodynamic evaluation of an all-comers study cohort using the dimensionless aortic regurgitation index (AR-index).
    Stundl A; Lucht H; Shamekhi J; Weber M; Sedaghat A; Mellert F; Grube E; Nickenig G; Werner N; Sinning JM
    PLoS One; 2019; 14(5):e0217544. PubMed ID: 31150455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre European registry to evaluate the Direct Flow Medical transcatheter aortic valve system for the treatment of patients with severe aortic stenosis.
    Naber CK; Pyxaras SA; Ince H; Frambach P; Colombo A; Butter C; Gatto F; Hink U; Nickenig G; Bruschi G; Brueren G; Tchétché D; Den Heijer P; Schillinger W; Scholtz S; Van der Heyden J; Lefèvre T; Gilard M; Kuck KH; Schofer J; Divchev D; Baumgartner H; Asch F; Wagner D; Latib A; De Marco F; Kische S
    EuroIntervention; 2016 Dec; 12(11):e1413-e1419. PubMed ID: 27934611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve.
    Gonska B; Seeger J; Keßler M; von Keil A; Rottbauer W; Wöhrle J
    Clin Res Cardiol; 2017 Aug; 106(8):590-597. PubMed ID: 28283746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procedural Outcome and Midterm Survival of Lower Risk Transfemoral Transcatheter Aortic Valve Implantation Patients Treated With the SAPIEN XT or SAPIEN 3 Device.
    Vendrik J; van Kesteren F; van Mourik MS; Piek JJ; Tijssen JG; Henriques JPS; Wykrzykowska JJ; de Winter RJ; Driessen AHG; Kaya A; Vis MM; Koch KT; Baan J
    Am J Cardiol; 2018 Apr; 121(7):856-861. PubMed ID: 29415808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New generation devices for transfemoral transcatheter aortic valve replacement are superior compared with last generation devices with respect to VARC-2 outcome.
    Seeger J; Gonska B; Rottbauer W; Wöhrle J
    Cardiovasc Interv Ther; 2018 Jul; 33(3):247-255. PubMed ID: 28643214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.